Atracurium Besylate

CHEMBL1200527 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1243.5 g/mol

LogP

—

Phase

4

The besylate salt of atracurium, used intravenously during anesthesia to relax skeletal muscles and allow endotracheal intubation. Its spontaneous degradation in plasma makes it predictable and suitable for patients with liver or kidney problems.

Moleküler Ağırlık

1243,5000 g/mol

TPSA

258,00 Å²

Terapötik Alanlar

Pain Management Asthma Chronic Kidney Disease Obesity Hypertension Breast Cancer Chronic Pain Atrial Fibrillation Colorectal Cancer

Etki Mekanizması

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1

InChI

InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2

Molecular Formula

C65H82N2O18S2

HBD / HBA

- / 18

Döndürülebilir Bağlar

26

Ağır Atomlar

87

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The besylate salt of atracurium, used intravenously during anesthesia to relax skeletal muscles and allow endotracheal intubation. Its spontaneous degradation in plasma makes it predictable and suitable for patients with liver or kidney problems.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Atracurium Besylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200527. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 47320. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Atracurium Besylate PillFYI'da

Yapı

Hızlı Veriler

Formül: C65H82N2O18S2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Atracurium Besylate

Terapötik Alanlar

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget